Lanne G, Kinderås M, Ling C, Brodtkorb TH. How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S201. doi: 10.1016/j.jval.2023.09.1028
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).